title: Prolyl hydroxylase domain 2 protein is a strong prognostic marker in human gastric cancer.
abstract: OBJECTIVE
  According to recent research, prolyl hydroxylase domain 2 protein (PHD2) plays an important role in human carcinogenesis by inducing neovascularization and tumor growth. The aim of this study was to evaluate PHD2 expression patterns in primary gastric adenocarcinoma and to test for a potential predictive value of PHD2 expression in gastric cancer patients.
  
  
  METHODS
  In a total of 121 patients, PHD2 expression was investigated by immunohistochemistry in paraffin-embedded tissue and correlated with clinicopathological parameters and patient survival.
  
  
  RESULTS
  64 of 121 gastric carcinomas (52.9%) showed PHD2 expression in tumor cell cytoplasm. In univariate analysis, PHD2-negative patients had a significantly shortened survival in comparison with PHD2-postive patients (19.5 vs. 32.7 months, p = 0.02). Independent prognostic significance could be shown in multivariate analysis for PHD2 expression (p = 0.005), age at diagnosis (p = 0.012), lymph node status (p = 0.016) and R status (p = 0.026).
  
  
  CONCLUSIONS
  Cytoplasmic PHD2 expression has a strong impact on survival in gastric cancer patients. Therefore, PHD2 represents a useful predictive biomarker in the evaluation of high-risk patients. Furthermore, these results underline the importance of PHD2 in gastric carcinogenesis and may identify PHD2 as a putative target for future gastric cancer therapy.
authors.affiliation: Department of General, Visceral and Transplantation Surgery, Charité University Hospital, Berlin, Germany. carsten.kamphues@charite.de
authors.forename: Carsten
authors.initials: C
authors.lastname: Kamphues
authors.forename: Daniel
authors.initials: D
authors.lastname: Wittschieber
authors.forename: Frederick
authors.initials: F
authors.lastname: Klauschen
authors.forename: Atsuko
authors.initials: A
authors.lastname: Kasajima
authors.forename: Manfred
authors.initials: M
authors.lastname: Dietel
authors.forename: Sven-Christian
authors.initials: SC
authors.lastname: Schmidt
authors.forename: Matthias
authors.initials: M
authors.lastname: Glanemann
authors.forename: Marcus
authors.initials: M
authors.lastname: Bahra
authors.forename: Peter
authors.initials: P
authors.lastname: Neuhaus
authors.forename: Wilko
authors.initials: W
authors.lastname: Weichert
authors.forename: Albrecht
authors.initials: A
authors.lastname: Stenzinger
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism* / Q000401:mortality / Q000473:pathology*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000378:metabolism*; D005260:Female; D006801:Humans; D064799:Hypoxia-Inducible Factor-Proline Dioxygenases; D008297:Male; D008875:Middle Aged; D011393:Procollagen-Proline Dioxygenase / Q000378:metabolism*; D011379:Prognosis; D013274:Stomach Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology*; D016019:Survival Analysis
chemical_list: D014408:Biomarkers, Tumor; C490190:EGLN1 protein, human; D011393:Procollagen-Proline Dioxygenase; D064799:Hypoxia-Inducible Factor-Proline Dioxygenases